Older age is a significant risk factor for serious illness and death for COVID-19, particularly when combined with significant underlying health conditions.
Today’s data shows that 100% of the deaths were people over 60; averaging out to 98% for the last 7 days.
Vaccine Efficacy Against Death Once Hospitalised
Vaccine Efficacy Against Death Once Hospitalised for the 30th of January, 2022 was calculated to be NEGATIVE at -20%.
The 7 day moving average was calculated to be NEGATIVE at -31% (247 lives lost).
Vaccine effectiveness against death once hospitalised simply looks at the latest known hospital occupancy of the vaxxed verses the unvaxxed and the deaths associated with the same cohort.
This calculation is measuring severe cases (hospitalised patients) and then comparing them against the final outcome and the number of deaths for this cohort. Vaccination rate of the population is irrelevant for this calculation as this method does NOT allow the vaccine to receive glory for vaxxing the young and healthy. This formula is a better measuring stick as it shows the true vaccine efficacy (protection) of the vulnerable (older age groups) once hospitalised.
We know that COVID-19 disproportionately targets the elderly and sadly the publicly available data provided by NSW Health is incomplete and we do not know the age breakdown of the people in hospital hence our limitations to draw authoritative conclusions. Sometimes they mention a particular individual with all the details but this is not the standard for all. Therefore the vaccine efficacy once hospitalised against death as calculated here should be treated as a rough guide and should only be applied to the older vulnerable age groups (+50) as they are the ones that are dying and that this data is representing. I will attempt to access all the required data but at this stage these —real world— numbers are what we have to work with.
Patients in hospital:
*Data taken from the COVID-19 Risk Management Dashboard put out by NSW Health on the 19th of January. Please see screenshot at the bottom of page with link to the original document.
Sadly, we are today reporting the deaths of 52 people with COVID-19; 33 men and 19 women.
Of the 52 people who died; three people were in their 60s, 11 people were in their 70s, 26 people were in their 80s, 11 people were in their 90s, and one person was aged more than 100 years old.
One person who died was aged under 65. The man, aged in his 60s, had received two doses of a COVID-19 vaccine and had significant underlying health conditions.
Six of the 52 people who died had received three doses of a COVID-19 vaccine, 32 people had received two doses, two people had received one dose, and 12 people were not vaccinated.
Triple Vaxxed 6 ppl (11.5%)
Double Vaxxed 32 ppl (61.5%)
Partially Vaxxed 2 ppl (3.8%)
Unvaxxed 12 ppl (23.1%)
*Data taken from NSW Health twitter update with links to the tweets further down this page. From today the partially vaccinated have been added to the vaccinated because they were either injured by the vaccine and could not take the second shot or it is a direct result of vaccinating during a pandemic which has its own risks for the first 10 days after each shot and is part of the risks attributed to mass vaccination of the whole population.
*Above data table shows the calculation to obtain Vaccine Efficacy Against Death Once Hospitalised.
Vaccine Efficacy Against Death Once Hospitalised for January 30, 2022:
= NEGATIVE -19.8%.
Seven Day Average:
The 7 Day Moving Average Vaccine Efficacy Against Death Once Hospitalised for the period starting from January 24, 2022 to January 30, 2022
= NEGATIVE -31%
Deaths by Dose, Comorbidity And Age Breakdown
*We do not get a detailed list of vaccine status for each case and age group but we do get totals per age group and sometimes they give us the comorbidity details as well.
Hospital Occupancy Data By Vaccine Status Was taken From The COVID-19 Risk Management Dashboard
Please remember I currently do not have access to detail mortality data broken down by age and vaccine status so the signal reliability will be crude and perhaps should only be applied to get an indication how well the vaccine protect the vulnerable (elderly).